
EnTox Sciences provides analytical tools for examining living tissue to life science and pharmaceutical sectors.
Founded with the mission to support life science researchers and the pharmaceutical industry, EnTox Sciences provides advanced analytical tools designed to investigate metabolic, signaling, and secretory functions in living tissue. Their flagship product, the Barofuse, along with complementary tools like the fraction collector module, Barofuse UI, and enclosure module, addresses critical challenges in biomedical research. By offering these innovative solutions, EnTox Sciences aims to enhance the efficiency and accuracy of early-stage physiological studies.
EnTox Sciences has garnered attention for its significant contributions to the field of biomedical research. The company is backed by a team of experts in analytical instrumentation and life sciences, though specific notable individuals and investors are not detailed. Their achievements include the successful deployment of their instruments in various research settings, which has led to improved understanding of human physiology and more effective drug development processes. Overall, EnTox Sciences has made a substantial impact by providing essential tools that streamline and advance biomedical research.

Insightful Science
Thermo Fisher th
thermofisher.com

Exum Instruments

Fluidigm
standardbio.com

Entopsis
entopsis.com

Enzium
enziumlabs.com

Attometrics

Isolation Sciences

ProForma Labs
proformalabs.com
Paracelsian

Hardin Scientific

Calibre Scientific
Stillwater Scientific Instruments

BioLum Sciences
biolumsciences.com

AvanSci Bio
avanscibio.com
Companies similar to EnTox Sciences include Insightful Science, Thermo Fisher th, Exum Instruments and Fluidigm.
EnTox Sciences was founded in 2013.
EnTox Sciences' headquarters is located in Mercer Island, WA, US.
EnTox Sciences' most recent funding round was for $900k (USD) in April 2019.
As of Apr 25, 2019, EnTox Sciences has raised a total of $1.1M (USD).
EnTox Sciences has 6 employees as of Feb 4, 2024.